The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team
Open accessAbstract
Background & aims Hepatocellular cancer (HCC) commonly complicates chronic liver disease and increases in incidence have been reported despite falling prevalences of viral hepatitis.Methods Following the introduction of centralised specialist teams to manage patients with cancer in England, we characterised the demographics of patients with HCC referred to the Newcastle-upon-Tyne Hospitals NHS Foundation Trust between 2000 and 2010. Regional HCC mortality data was from Public Health England.Results HCC related mortality in the region rose 1.8 fold in 10 years, from 2.0 to 3.7 per 100,000. 632 cases were reviewed centrally, with 2-3 fold increases in referrals of patients with associated hepatitis C, alcoholic liver disease or no chronic liver disease and a >10 fold increase in HCC associated with non-alcoholic fatty liver disease (NAFLD). By 2010 NAFLD accounted for 41/118 (34.8%) cases. Irrespective of associated etiologies, metabolic risk factors were present in 78/118 (66.1%) cases in 2010, associated with regional increases in obesity and diabetes. Median overall survival was just 10.7 months. Although patients with NAFLD associated HCC were older (71.3 yr vs. 67.1 yr; p<0.001) and their cancers less often detected by surveillance, their survival was similar to other etiologies. This was attributed to significantly higher incidental presentation (38.2%) and lower prevalence of cirrhosis (77.2%).Conclusions HCC related mortality is increasing, with typical patients being elderly with metabolic risk factors. The prognosis for most of the cases is poor, but older patients with co-morbidities can do well, managed, within a specialist multidisciplinary team if their cancer is detected pre-symptomatically.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a tertiary centre for HCC referral in Northern England, 231 individuals with HCC due to MASLD had a lower prevalence of cirrhosis (77.2%) than those with other aetiologies.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [231]
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,913
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Estimates of the cancer incidence and mortality in Europe in 2006
Ferlay, J., Autier, P., Boniol, M., Heanue, M., Colombet, M., & Boyle, P. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl498 · Cited by 4,032
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Estimates of cancer incidence and mortality in Europe in 2008
Ferlay, J., Parkin, D. M., & Steliarova‐Foucher, E. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2009.12.014 · Cited by 2,323
Nonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
Neuschwander‐Tetri, B. A., & Caldwell, S. H. (2003) · Hepatology · doi:10.1053/jhep.2003.50193 · Cited by 2,166
Ascha, M. S., Hanouneh, I. A., Lopez, R., Tamimi, T. A.-R., Feldstein, A. F., & Zein, N. N. (2010) · Hepatology · doi:10.1002/hep.23527 · Cited by 1,296
Cited by
Sorted by citations
Items 601–609 of 609
New radiomics approaches for hepatic tumor characterization through imaging analysis
Ouhmich, F. (2021) · theses.fr (ABES) · doi:10.70675/b5d050c9zbcc8z4ba2z8e59z8b953b2cebea
Hepatocellular carcinoma in F0 livers: Clinical and prognostic insights
Endo, M., Honda, K., Tokumaru, T., Saito, T., Uchida, T., Iwao, M., Arakawa, M., Seike, M., Kodama, M., Masuda, T., et al. (2026) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v18.i4.115576
Anand, M., & Waan, S. (2026) · Hippocratic Journal of Unani Medicine · doi:10.4103/hjum.hjum_104_25
Shekar, V., & Lucke-Wold, B. P. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.118374
Fernández, C. B., Rivas, S. B., Ávila, V. B., Castro, R. Q., Ruiz, S. D., Vega, L. A., Martín, L. R., Pascual, L. A., Álvarez, P. S., & Rodríguez, R. D. (2026) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2026.12004/2026
Jones, E., Eppler, N., Ahamed, F., & Zhang, Y. (2026) · Livers · doi:10.3390/livers6040074 · Cited by 2
“Furthermore, metabolic syndromes, such as obesity, insulin resistance, dyslipidemia, and diabetes mellitus, have also been linked to an increased risk of HCC, owing to insulin resistance and chronic inflammation [64,69–71].”
Villani, R., & Serviddio, G. (2026) · Annals of Hepatology · doi:10.1016/j.aohep.2026.102434
Combining antiviral therapy with cancer treatment in HBV-associated HCC: A translational approach
Hashem, M., Kayesh, M. E. H., Kohara, M., & Tsukiyama-Kohara, K. (2026) · Virus Research · doi:10.1016/j.virusres.2026.199812
“…chronic inflammation, oxidative stress, and fibrotic remodeling, together with host factors such as age, sex, metabolic dysfunction, alcohol consumption, and HBV genotype, all of which shape tumor initiation, progression, and clinical behavior (Dyson et al., 2014; El-Serag and Rudolph, 2007).”
Zhang, X., Dong, Y., Xiao, Y., Li, C., Wang, D., Zou, J., & Jiang, X. (2026) · International Journal of Clinical Practice · doi:10.1155/ijcp/5262469
Metadata
- Authors
- Dyson, J., Jaques, B., Chattopadyhay, D., Lochan, R., Graham, J., Das, D., Aslam, T., Patanwala, I., Gaggar, S., Cole, M., Sumpter, K., Stewart, S., Rose, J., Hudson, M., Manas, D., & Reeves, H. L.
- Affiliations
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- Newcastle University (GB)
- Corresponding author
- Reeves, Helen L.
- ORCID
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2014-01
- Volume
- 60
- Issue
- 1
- Pages
- 110-117
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2076341209
- Cited by
- 603
- References
- 25
- Citations by year
- 2026: 23 · 2025: 32 · 2024: 45 · 2023: 43 · 2022: 72 · 2021: 65 · 2020: 63 · 2019: 60 · 2018: 57 · 2017: 48 · 2016: 38 · 2015: 33 · 2014: 18
- FWCI
- 19.26
- Type
- journal article
- Language
- en
- Open access
- green
- zenodo.org
- Licence
- Locations
- Journal of Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, other-oa)
- Newcastle University ePrints (Newcastle Univesity)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Keywords
- hepatocellular carcinoma, obesity, type 2 diabetes, non-alcoholic fatty liver disease, HCC mortality, chronic liver disease, hepatitis C, alcoholic liver disease, metabolic risk factors, multidisciplinary cancer care, cancer surveillance, liver cirrhosis, overall survival, cancer incidence trends
- MeSH terms
- Age Factors, Aged, Diabetes Mellitus, Type 2, Fatty Liver, Humans, Liver Neoplasms, Middle Aged, Obesity, Risk Factors, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review